BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29053158)

  • 21. Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study.
    Gupta R; Dahiya M; Kumar L; Shekhar V; Sharma A; Ramakrishnan L; Sharma OD; Begum A
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e345-e350. PubMed ID: 29980412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].
    Ruiz-Delgado GJ; Gómez Rangel JD
    Gac Med Mex; 2004; 140(4):375-9. PubMed ID: 15456147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of monoclonal gammopathy of undetermined significance in Shenzhen, China.
    Xu A; Guo T; Zhang S; Luo H; Shen M; Ye Y; Ji L
    Hematology; 2024 Dec; 29(1):2352686. PubMed ID: 38819332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
    Grass S; Preuss KD; Ahlgrimm M; Fadle N; Regitz E; Pfoehler C; Murawski N; Pfreundschuh M
    Lancet Oncol; 2009 Oct; 10(10):950-6. PubMed ID: 19767238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
    Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
    Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
    Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
    Guerard EJ; Tuchman SA
    Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS).
    Pang L; Rajkumar SV; Kapoor P; Buadi F; Dispenzieri A; Gertz M; Lacy M; Kyle R; Kumar S
    Blood Cancer J; 2021 Feb; 11(2):26. PubMed ID: 33563898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
    Rögnvaldsson S; Aspelund T; Thorsteinsdóttir S; Turesson I; Björkholm M; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Jul; 107(1):137-144. PubMed ID: 33840154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.
    Goebel TE; Schiltz NK; Woodside KJ; Pillai AC; Caimi PF; Lazarus HM; Koroukian SM; Campagnaro EL
    Clin Transplant; 2015 Sep; 29(9):851-7. PubMed ID: 26194021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
    Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
    Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary intake is associated with risk of multiple myeloma and its precursor disease.
    Thordardottir M; Lindqvist EK; Lund SH; Costello R; Burton D; Steingrimsdottir L; Korde N; Mailankody S; Eiriksdottir G; Launer LJ; Gudnason V; Harris TB; Landgren O; Torfadottir JE; Kristinsson SY
    PLoS One; 2018; 13(11):e0206047. PubMed ID: 30383820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
    Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
    Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
    Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
    Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [50-year-old man with fatigue and monoclonal gammopaty].
    Raeder H; Kildahl-Andersen O; Stalsberg H
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2677-9. PubMed ID: 17972388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.